The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience

详细信息    查看全文

• 作者：Shalini Moningi BA ; Avani S. Dholakia BS ; Siva P. Raman MD…
• 刊名：Annals of Surgical Oncology
• 出版年：2015
• 出版时间：July 2015
• 年：2015
• 卷：22
• 期：7
• 页码：2352-2358
• 全文大小：478 KB
• 参考文献：1.Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-0.PubMed View Article
  2.Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-7.PubMed View Article
  3.Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91(5):586-4.PubMed View Article
  4.Mahadevan A, Jain S, Goldstein M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010;78(3):735-2.PubMed View Article
  5.Chuong MD, Springett GM, Freilich JM, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013;86(3):516-2.PubMed View Article
  6.Iyengar P, Westover K, Timmerman RD. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer. Semin Respir Crit Care Med. 2013;34(6):845-4.PubMed View Article
  7.Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25(8):947-2.PubMed View Article
  8.Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58(4):1017-1.PubMed View Article
  9.Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;63(2):320-.PubMed View Article
  10.Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008;72(3):678-6.PubMed View Article
  11.Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76(1):48-3.PubMed View Article
  12.Callery MP, Chang KJ, Fishman EK, Talamonti MS, Traverso WL, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol. 2009;16(7):1727-3.PubMed View Article
  13.Pawlik TM, Laheru D, Hruban RH, et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol. 2008;15(8):2081-.PubMed Central PubMed View Article
  14.Khashab MA, Kim KJ, Tryggestad EJ, et al. Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. Gastrointest Endosc. 2012;76(5):962-1.
  15.Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-7.PubMed View Article
  16.Patel M, Hoffe S, Malafa M, et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011;104(2):155-1.PubMed Central PubMed View Article
  17. http://?www.?sciencedirect.?com/?science/?article/?pii/?S009377541400284?X .
  18.Goyal K, Einstein D, Ibarra RA, et al. Stereotactic body radiation therapy for nonresectable tumors of the pancreas. J Surg Res. 2012;174(2):319-5.PubMed Central PubMed View Article
  19.Polistina F, Costantin G, Casamassima F, et al. Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010;17(8):2092-01.PubMed View Article
  20.Rwigema JC, Parikh SD, Heron DE, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2011;34(1):63-.PubMed View Article
  21.Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115(3):665-2.PubMed View Article
  22.Rajagopalan MS, Heron DE, Wegner RE, et al. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiat Oncol. 2013;8:254-717X-8-254.
  
• 作者单位：Shalini Moningi BA (1)
  Avani S. Dholakia BS (1)
  Siva P. Raman MD (2)
  Amanda Blackford Sc.M (1)
  John L. Cameron MD (3)
  Dung T. Le MD (4)
  Ana M. C. De Jesus-Acosta MD (4)
  Amy Hacker-Prietz MS (1)
  Lauren M. Rosati BS (1)
  Ryan K. Assadi BS (1)
  Shirl Dipasquale RN (1)
  Timothy M. Pawlik MD (3)
  Lei Zheng MD (4)
  Matthew J. Weiss MD (3)
  Daniel A. Laheru MD (4)
  Christopher L. Wolfgang MD (3)
  Joseph M. Herman MD (1)
  
  1. Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  2. Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  3. Department of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  4. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  
• 刊物主题：Surgical Oncology; Oncology; Surgery;
• 出版者：Springer US
• ISSN：1534-4681

文摘

Background Stereotactic body radiation therapy (SBRT) is a promising option for patients with pancreatic cancer (PCA); however, limited data support its efficacy. This study reviews our institutional experience of SBRT in the treatment of locally advanced (LAPC) and borderline resectable (BRPC) PCA. Methods Charts of all PCA patients receiving SBRT at our institution from 2010 to 2014 were reviewed. Most patients received pre-SBRT chemotherapy.?Primary endpoints included overall survival (OS) and local progression-free survival (LPFS). Patients received a total dose of 25-3?Gy in five fractions. Results A total of 88 patients were included in the analysis, 74 with LAPC and 14 with BRPC. The median age at diagnosis was 67.2?years, and median follow-up from date of diagnosis for LAPC and BRPC patients was 14.5 and 10.3?months, respectively. Median OS from date of diagnosis was 18.4?months (LAPC, 18.4 mo; BRPC, 14.4 mo) and median PFS was 9.8?months (95?% CI 8.0-2.3). Acute toxicity was minimal with only three patients (3.4?%) experiencing acute grade ? toxicity. Late grade ? gastrointestinal toxicity was seen in five patients (5.7?%). Of the 19 patients (21.6?%) who underwent surgery, 79?% were LAPC patients and 84?% had margin-negative resections. Conclusions Chemotherapy followed by SBRT in patients with LAPC and BRPC resulted in minimal acute and late toxicity. A large proportion of patients underwent surgical resection despite limited radiographic response to therapy. Further refinements in the integration of chemotherapy, SBRT, and surgery might offer additional advancements toward optimizing patient outcomes.